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ABSTRACT
Purpose The introduction of intra-arterial
chemotherapy (IAC) as salvage treatment has improved
the prognosis for eye conservation in group D
retinoblastoma. The aim of this study was to compare
the outcomes of consecutive patients with advanced
unilateral disease treated with either ﬁrst-line intravenous
chemotherapy (IVC) or ﬁrst-line IAC.
Design This is a retrospective mono-centric comparative
review of consecutive patients.
Patients Sporadic unilateral retinoblastoma group D
cases treated conservatively at Jules-Gonin Eye Hospital
and CHUV between 1997 and 2014. From January
1997 to August 2008, IVC, combined with focal
treatments, was the primary treatment approach. From
September 2008 to October 2014, IAC replaced IVC as
ﬁrst-line therapy.
Methods 48 patients met the inclusion criteria,
receiving only either IAC or IVC as primary treatment
modality.
Results Outcomes of 23 patients treated by IVC were
compared with those of 25 treated by IAC; mean follow-
up was 105.3 months (range 29.2–218.6) and 41.7
months (range 19.6–89.5), respectively. Treatment
duration was signiﬁcantly shorter in the IAC group
(p<0.001). Ten eyes in the IVC group underwent
enucleation. Recordable visual acuity of the salvaged
eyes was signiﬁcantly better in the IAC group (0.9 vs 1.4
logarithm of the minimum angle of resolution, p<0.01).
No extraocular disease, metastases or long-term systemic
complications were observed in either group.
Conclusions The difference in the time frame between
treatment groups had an impact on the availability of
intravitreal chemotherapy treatment. Despite this, the
results reported here imply that eyes treated with ﬁrst-
line IAC will have shorter treatment period, better ocular
survival and visual acuity than ﬁrst-line IVC.
INTRODUCTION
Over the past two decades, ﬁrst-line conservative
management of advanced bilateral retinoblastoma
(IIRB1 group D) has moved from external beam
radiotherapy (EBR) to intravenous chemotherapy
(IVC), consolidated by focal treatments (FTs).
Globe salvage in bilateral group D retinoblastoma
(Rb) at 5 years was 47% with six cycles of IVC
alone; this can be increased to 68% when com-
bined with low-dose (36 Gy) intensity-modulated
radiation therapy in cases of relapse.2 3 Reported
functional outcome is poor, especially when the
macula is involved.4–10 Due to the low salvage rate
and poor visual outcome after IVC, enucleation
historically remained the treatment of choice in
many cases of unilateral group D Rb.2 11–14
Intra-arterial chemotherapy (IAC) has emerged
as an alternative to enucleation or EBR in eyes
with tumour recurrence or drug resistance follow-
ing IVC.11 15–22 Schaiquevich et al23 showed sig-
niﬁcantly higher salvage rates with IAC than
sequential periocular topotecan and a second
course of IVC in eyes with failed ﬁrst-line IVC.
Despite discrepancies in classiﬁcation, several
studies on ﬁrst-line and salvage IAC for group D
Rb have reported high globe retention
rates.15 18 24–26 In a survey by Grigorovski et al27
comprising 31 treatment centres, IAC was
reported as ﬁrst-line treatment by the majority
(74%) for unilateral advanced disease. To date,
visual outcomes with ﬁrst-line IVC are poor, espe-
cially when there is macular involvement.5
To the best of our knowledge, there has been no
prospective study completed comparing IAC with
IVC as ﬁrst-line treatment for group D Rb.28 This
study is a retrospective systematic review of con-
secutive patients with sporadic unilateral group D
Rb treated at the Jules-Gonin Eye Hospital by
either ﬁrst-line IAC or IVC to estimate eye reten-
tion rates, visual prognosis and systemic or ocular
adverse occurrence rates.
METHODS
Patients
This retrospective study was approved by the
ethical committee of Vaud, Switzerland (authorisa-
tion # 2016-00149), and compliant with the
Declaration of Helsinki. All consecutive patients
with sporadic unilateral retinoblastoma treated con-
servatively between 1997 and 2014 at Jules-Gonin
Eye Hospital and the CHUV were included.
Exclusion criteria were other primary treatments
undertaken (including IAC/IVC started at a differ-
ent treatment centre), patients receiving both IVC
and IAC during the course of treatment,
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Table 1 Baseline characteristics and consolidation/salvage treatment after first-line intra-arterial or intravenous chemotherapy
IAC IVC p Value
Number of eyes 25 23
Number of cycles/injections 2.7±0.5 3.0±0.8
Age (months) at first cycle/injection 33.3±25.9 19.2±15.2 0.01*
Baseline characteristics
Retinal detachment (n) 9 11 0.56†
Total retinal detachment 5 8
Partial retinal detachment 3 2
Peritumoral retinal detachment 1 1
None/reapplied 12/4 7/5
Macula
Intact 7 7
Damaged/absent 18 16 0.89
Subretinal seeding 9 10 0.77†
Vitreous seeding (No. of eyes) 20 14 0.21†
Localised 2 7
Diffuse 18 7
Consolidation treatment (No. of eyes)
CTT±focal CTP 0 9
CTT+IViC±focal CTP 0 1
CTT+PBT±focal CTP 0 1
PBT±focal CTP 0 2
Focal CTP only 5 5
IViC±focal CTP 9 0
IViC+POC±focal CTP 3 0
POC±focal CTP 3 0
None 5 1
Relapse (No. of eyes) 6 (24%) 12 (52%) 0.07†
Mean number of relapses 1.3 ±0.8 3.3±1.6 0.01*
Months to first relapse 6.3±2.5 8.5±3.8 0.61*
At primary tumour site (n) 0 8
Subretinal seeding (n) 2 7
Vitreous seeding (n) 4 4
None 19 7
Salvage treatment (No. of eyes) 6 12 0.07†
CTT+PBT±focal CTP 0 1
PBT±focal CTP 0 3
POC±focal CTP 0 1
IViC+POC±focal CTP 0 1
IViC+POC+PBT±focal CTP 0 1
IViC±focal CTP 3 0
IViC+PBT±focal CTP 1 0
Focal CTP only 1 5
IAC (repeat)+IViC+focal CTP 1 0
Outcome
Enucleated eyes (n) 0 10 (43%) <0.001†
Progressive disease – 9
Phthisis bulbi – 1
Time to complete response
Retained eyes 6.7±3.0 14.2±6.5 <0.001*
Globe survival from first cycle/injection (months) 33.0± 17.7 62.7± 55.7
Enucleated eyes – 16.5 (0.8–48.4)
Retained eyes 33.0± 17.7 91.4±54.3
Event-free interval for retained eyes (months) 28.2 (3.5–67.9) 78.5 (4.7–203.4)
Patient survival 33.3 (9.1–75.1) 100.5 (19.3–218.6)
Final visual acuity logMAR (median and IQR) 0.7 [0.2–1.0] 1.4 [1.2–2.0] 0.01
*Mann-Whitney U test.
†Fisher’s exact test.
CTT, chemothermotherapy; focal CTP, cryocoagulation±thermotherapy±photocoagulation; IAC, intra-arterial chemotherapy; IVC, intravenous chemotherapy; IViC, intravitreal
chemotherapy; logMAR, logarithm of the minimum angle of resolution; PBT, plaque brachytherapy; POC, periocular chemotherapy.
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consultation for second opinion only and cases with bilateral
disease. Diagnosis was based on ophthalmological examination
under general anaesthesia, with RetCam images and ultrasound
recorded by the same ocular oncologist (FLM). Eyes were
grouped according to the International Intraocular
Retinoblastoma Classiﬁcation (IIRC) classiﬁcation1 (patients
prior to 2005 reclassiﬁed from Reese-Ellsworth).29 During the
study period, 231 consecutive patients were referred for unilat-
eral Rb, of which 148 met the inclusion criteria, including 120
with advanced disease, that is, 75 group D and 45 group E. All
but one of group E eyes underwent primary enucleation
(97.8%) and in group D 22 were enucleated (29.3%) (20 of 36
cases prior to 2008 (56%) and 2 of 39 cases since 2008 (5%)).
Fifty-three patients with group D and one group E were
treated conservatively with IVC and/or IAC. Five patients were
treated with combination IAC/IVC (including the group E eye)
and one did not comply with the treatment protocol, resulting
in 48 records for analysis. Informed consent was obtained
(MB-P). A cerebral MRI was performed to exclude trilateral Rb
or extraocular extension. If the optic nerve head was not fully
visible or was in contact with the tumour, a spinal tap was
obtained to exclude central nervous system extension. Prior to
IVC, a complete blood cell count, renal (plasma creatinine and
urea) and hepatic (aspartate-aminotransferase, alanine-amino-
transferase and bilirubin) assessment, and auditive evoked
potentials were systematically recorded. From January 1997 to
August 2008, IVC, combined with FTs, was the primary treat-
ment approach. From September 2008 to October 2014, IAC
replaced IVC as ﬁrst-line therapy except in children weighing
<6 kg or after IAC unsuccessful procedure attempt.
Intravenous chemotherapy
IVC was given over 3 days, every three weeks or at an absolute
neutrophil count of ≥1000×106/L and thrombocyte count of
≥100 000×106/L after the nadir, as follows: etoposide 150 mg/
m2/day diluted in 125–250 mL NaCl 0.9% intravenously over
1 hour and with carboplatin 200 mg/m2/day diluted in 125–
250 mL glucose 5% intravenously over 1 hour, both on days 1–
3. In children under 1 year of age or weighing <10 kg, the
dosage was adapted to weight (5 mg/kg/day for etoposide and
6.7 mg/kg/day for carboplatin). Chemotherapy was initiated
within 24–48 hours after the ophthalmological examination.30
Chemotherapy was stopped as soon as it was possible to treat
the tumour(s) with FT alone (cryotherapy, photocoagulation,
thermotherapy, chemothermotherapy and brachytherapy) or
continued up to a maximum of ﬁve.
Intra-arterial chemotherapy
IAC was performed on an outpatient basis (1 day) under general
anaesthesia with systemic intravenous heparinisation (25–70 IU/
kg). A 3 or 4 French introducer sheath was placed in the
common femoral artery using the Seldinger technique. The
internal carotid artery was then accessed with a guiding catheter
over a 0.018-inch guide wire under ﬂuoroscopic guidance. A
heparinised saline ﬂush was connected to the guiding catheter
during the entire procedure. After a baseline cerebral angio-
gram, a 1.2 or 1.5 French microcatheter (Baltacci or Magic, Balt
Extrusion, Montmorency, France) mounted on a 0.007-inch
microguide wire (Hybrid, Balt Extrusion, Montmorency,
France) was navigated to the ostium of the ophthalmic artery.
After ﬂuoroscopic conﬁrmation of the correct positioning of the
microcatheter tip, and the absence of contrast reﬂux in the
internal carotid artery, a melphalan dose prepared according to
weight (range 2.8–7.5 mg adjusted to 30 mL) was infused over
30 min (1 mL/min) according to the pulsatile injection tech-
nique.16 A ﬁnal cerebral angiogram was obtained to exclude any
thromboembolic events before removing the endovascular
material. Chemotherapy was stopped as soon as it was possible
to treat the tumour(s) with FT alone or continued up to a
maximum of three.
Consolidation/salvage
Prior to each chemotherapy cycle, the necessity to continue IVC
or IAC was determined based on the amenability to consolida-
tion treatments or FT. For lesions not ﬂat or calciﬁed, sequential
intensive FT was performed.31 In 2008, intravitreal melphalan
was added to the FT armamentarium for persistent or recurrent
vitreous disease.32 Tumour control was achieved and classiﬁed
according to complete regression of retinal tumour type 0–433
and vitreous type 0–3.34 After ﬁrst-line and consolidation ther-
apies, an observation period was initiated. In cases of relapse
that were possible to treat with salvage therapy, then all treat-
ment modalities were considered except IVC and EBR.
Patient follow-up
After completion of IVC or IAC, amblyopia therapy was
initiated, with the patching regimen adapted to age, collabor-
ation and success. At last control visual acuity was recorded:
indication of the presence/absence of light perception or best
corrected visual acuity (BCVA) recorded as follows depending
on age: Teller cards (<30 months); Lea symbols (Good-light
Inc, Elgin, Il, USA) (30 months to 4 years); Snellen ‘E’ chart (4–
5 years) and Snellen chart (>6 years). Visual acuities were con-
verted to logarithm of the minimum angle of resolution
(logMAR) values.35 Hand-held spectral-domain optical coher-
ence tomography recordings using the Bioptigen imaging system
(Durham, North Carolina, USA) were made in all salvaged eyes
to classify foveal structure into three categories: fovea, intact
damaged or absent.
Statistical analysis
Time to treatment completion and eye retention probability
were analysed using the Kaplan-Meier method and compared
between the IAC and IVC groups using the log-rank test statistic
at a 5% level of signiﬁcance using the ‘survival’ R package.36
Time to treatment completion was deﬁned by treatment start
date until tumour treatment was complete; data were censored
at the last visit or at the date of enucleation. Statistical analysis
was performed with the R software package V.2.15.1.37
RESULTS
In total, 23 patients treated with ﬁrst-line IVC, including two
cases where IAC was ﬁrst attempted but failed due to anatomical
factors, were compared with 25 cases with ﬁrst-line IAC. Two
cases of IAC required micro-catheterisation and chemotherapy
injection via the external carotid artery due to anatomical var-
iants of the ophthalmic artery. Mean follow-up for the IVC
group was 105.3 months (range 29.2–218.6) and for the IAC
group 41.7 months (range 19.6–89.5).
Duration of treatment to resolution or enucleation
All patients completed ﬁrst-line treatment, and the mean
number of cycles (IVC) or injections (IAC) was comparable
between groups (table 1). Tumour control was signiﬁcantly
faster in the IAC group (table 1 and ﬁgure 1). The number of
consolidation treatments was comparable for both groups, with
the IVC group receiving primarily chemothermotherapy as
second-line treatment and the IAC group beneﬁtting from
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intravitreal chemotherapy (IViC). All but one IVC eye (95.6%)
required consolidation therapy compared with 80% (n=20) in
the IAC group. In addition, relapse was observed at least once in
52% (n=12) of IVC vs 24% (n=6) of IAC eyes; IVC eyes had
signiﬁcantly more relapse (3.3 vs 1.3) and ﬁrst relapse happened
later than in IAC eyes (mean 6.3 vs 8.5 months) (table 1). The
number of anaesthetics required to achieve tumour control in
retained eyes was signiﬁcantly higher in the IVC group with a
mean number of 18 (range 5–38) compared with 9 (range 3–
23) for IAC (p<0.001). The event-free interval in retained eyes
of the IVC group up to last follow-up shows a mean
78.5 months (range 4.7–203.4) and that of the IAC group a
mean 28.2 months (range 3.5–67.9).
In order to examine data that were independent of IViC treat-
ments, a subgroup analysis was performed. In the IVC sub-
group, those eyes with diffuse vitreous seeding were excluded
(ie, those that would have been potentially treated with IViC,
n=16), and only eyes without IViC consolidation treatment
treatment were included in the IAC subgroup (n=13; this
included ﬁve eyes with diffuse vitreous seeding). Due to the
inclusion criteria of both groups, the IAC is expected to do
worse; however, in this subgroup analysis, we observed a higher
rate of relapse (63%), 10/16 vs (29%) 3/13, p=0.06, in the IVC
subgroup; also the mean number of anaesthetics was higher
(19.2 vs 7.5, p<0.001) in the IVC subgroup.
Globe survival and ﬁnal foveal structure
We observed that there was change in the primary enucleation
rate in unilateral retinoblastoma between 1997 and 2008 from
56% (n/N=20/36) to 5% since the introduction of IAC in 2008
(2/39). Prior to 2008, eyes were often enucleated due to massive
seeding (16 of the 20 cases) since 2008 no case of unilateral ret-
inoblastoma group D has been enucleated due to seeding. The
two enucleations were due to suspicion of optic nerve involve-
ment. Histological risk factors were not observed in any of the
cases of primary enucleation. This can be observed partially in
the number of eyes with diffuse vitreous seeding observed at
presentation, 72% in IAC vs 30% in IVC. None of the IAC
group required enucleation (ﬁgure 2). In the IVC group, 10
eyes were enucleated after an average 16.5 months of treatment
(range 0.8–48.4 months), 9 due to uncontrollable seeding and/
or total retinal detachment (RD) and 1 due to phthisis bulbi.
Figure 1 Kaplan-Meier curves showing the time to treatment success for the intra-arterial chemotherapy (IAC) and intravenous chemotherapy
(IVC). The log-rank statistic indicates that there is a signiﬁcant difference between the curves p<0.001.
Figure 2 Kaplan-Meier curves showing the eye retention rates with respect to time for the intra-arterial chemotherapy (IAC) and intravenous
chemotherapy (IVC). The log-rank statistic indicates that there is a signiﬁcant difference between the curves p<0.001.
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Excluding those eyes without diffuse vitreous seeding in the
IVC group (n=16), ﬁve eyes underwent subsequent enucleation.
Review of the 10 cases enucleated showed that at presentation
the macula was damaged/absent in 3 cases (30%) and intact in 7
cases (70%). OCT recordings taken at treatment completion for
the IVC 13 salvaged eyes showed the fovea to be damaged in 6
cases (46%), absent in 7 (54%); none was intact. In the IAC
group, OCT ﬁndings at treatment completion revealed the fovea
to be damaged in 14 (56%), absent in 4 (16%) and intact in 7
eyes (28%).
Functional outcomes
Amblyopia therapy was carried out in the majority of retained
eyes in both groups: IVC 11/13 (85%) and IAC 21/25 (84%).
Irrespective of macula status, daily patching of the healthy eye
(hours per day dependent on age and collaboration) was
initiated in all cases except one where no treatment was neces-
sary (ie, normal visual acuity).
In two cases in the IVC group and four of the IAC group
patching was discontinued due to poor visual prognosis and/or
lack of collaboration. Final visual acuity was signiﬁcantly better
in the IAC-treated eye (ﬁgure 3). In the IVC group, 1 of the 13
retained eyes had no detectable light perception. In the other 12
eyes, median visual acuity at last visit was 1.4 logMAR (IQR
1.2–3). Median visual acuity in contralateral eyes was 0.0
logMAR (IQR 0.0–0.0). In the IAC group, 22/25 eyes had light
perception or better, and median visual acuity at last visit was
0.9 logMAR (IQR 0.3–1.2). Median visual acuity in contralat-
eral eyes was 0.0 logMAR (IQR 0.0–0.0). The number of lines
lost in comparison to the contralateral eye is given in ﬁgure 3,
with a median of 6 lines (IQR 3–12) lost in the IAC group and
14 lines (IQR 12–31) lost in the IVC group (p=0.01).
Complications
Details of systemic and/or ocular complications are given in
table 2. There was no stroke, seizure, neurological impairment,
hearing loss, limb ischaemia, second non-ocular primaries,
metastasis or death in either cohort. There were signiﬁcantly
fewer, and less severe, systemic complications observed in the
IAC group. Eight patients in the IVC group required transfu-
sions versus none in the IAC group. Transient cardiorespiratory
disturbances were observed intraoperatively in four patients in
the IAC group but with no consequences. Following one
successful injection of IAC, spasticity of the internal carotid
artery in one patient resulted in the procedure being stopped
during the second injection. Two patients in the IVC group
were initially prescribed IAC, but the procedure was abandoned
in favour of IVC due to anatomical restrictions inhibiting
treatment.
In the ocular complications, secondary RD was observed in a
similar number of patients in both groups. A greater number of
IVC eyes receiving brachytherapy led to radiation-induced retin-
opathy (four eyes). In the IAC group, occlusive choroidopathy
was observed in three eyes but with macula sparing and good
visual acuity in one case. Melphalan-related retinopathy was
noted in three cases with grades 1–3 related to IViC therapy.34
DISCUSSION
To the best of our knowledge, this study is the second direct
comparison between IAC and IVC in unilateral group D retino-
blastoma as ﬁrst-line treatment. Although between the two
groups there are differences in the consolidation treatments
used, the globe retention was 100% when IAC was the ﬁrst-line
therapy compared with 57% in the IVC group. No metastases
or deaths occurred in either group. IAC was associated with
fewer side effects, faster and more extensive response rates,
fewer relapses and better visual acuity than the IVC-retained
Figure 3 A bar chart summarising the number of lines lost in treated
eye in comparison to contralateral healthy eye for intra-arterial
chemotherapy (IAC) (black) and intravenous chemotherapy (IVC) (grey)
treated eyes.
Table 2 Complications
Ocular complications IAC IVC
Retinal detachment (secondary): No. eyes 14 14
Total (N surgery) 9 (6) 7 (0)
Partial (N surgery) 4 (2) 5 (0)
Peritumoral 1 2
Retinopathy: No. eyes 8 (32%) 4 (17.4%)
Actinic (radiotherapy plaque-related) 0 4
Ischaemic 2 0
Occlusive choroidopathy 3 0
IViC-related melphalan retinopathy 3 0
Vitreous haemorrhage 1 5
Neovascularisation 2 0
Phthisis bulbi 0 1
Cataract: No. eyes (N surgery) 6 (0) 3 (3)
Transient ocular adnexa+forehead complications
Palpebral oedema 5 0
Palpebral erythema 1 0
Ptosis 1 0
Localised frontal hair loss 1 0
Transient systemic complications
Cardiorespiratory disturbances (No. patients) 4 0
Vasospasm (No. patients): 2 0
Internal carotid and/or ophthalmic artery 2 –
Neutropenia (No. patients): 3 5
Non-febrile grade 1 3 2
Febrile grade 3 0 3
Thrombocytopenia (No. patients) 0 6
Allergy to carboplatin/VP16 (No. patients) – 2
Anaemia (No. patients) 0 3
Transfusion: No. patients (N transfusions) 0 8 (11)
Blood transfusion 0 3 (3)
Transfusion thrombocytes 0 5 (8)
Nausea 4 5
IAC, intra-arterial chemotherapy; IVC, Intravenous chemotherapy; IViC, intravitreal
chemotherapy.
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eyes. During the study period for unilateral group D retinoblast-
oma, primary enucleation dropped from 56% to 5% after the
introduction of IAC and IViC in 2008. Moreover, in eyes that
were independent of IViC treatment (cf subgroup analysis),
relapses occurred more often in the IVC group.
Historically, IVC has been associated with poor eye retention
rates, with 25–47% of eyes preserved in Rb group D eyes.2 In
the present study, the eye retention rate was 57% at 5 years,
notably with three courses of IVC compared with the 6–9
monthly cycles for group D eyes administered by the majority
of treatment centres.1 In the recent publication by Shields et al
comparing directly IVC and IAC in retinoblastoma, in the
advanced treated eye (ie group D using the Philadelphia classiﬁ-
cation), similar numbers of eyes were examined. Although sur-
vival analysis was not performed and thus the rates cannot be
directly compared, lower globe survival rates of 48% in IVC
and 91% in IAC-treated eyes were reported. In our IAC cohort,
we report a 100% eye retention rate with mean follow-up of
41 months, comparing favourably with the retention rates (82–
100%) reported in the literature with a notably shorter mean
follow-up (12–24 months).25 26 The higher retention rate
reported here may be related to the more intensive FT protocol
implemented at our centre and the early introduction of IViC
treatments.
Tumour control was achieved sooner with IAC and with
fewer relapses. Diffuse vitreous seeding was more frequent at
presentation in the IAC group, but while these patients beneﬁt-
ted from consolidation and/or salvage IViC, this was a factor for
enucleation in the IVC group. However, of the six cases in the
IVC that relapsed and were subsequently enucleated, only three
had vitreous seeding. The principal secondary complication in
both cohorts was RD (table 2). In the IAC group, RD surgery
without drainage was carried out in eight cases with successful
reapplication; for the IVC group, this would also have been
considered a contributing factor for enucleation. On closer
review of the IVC cases that resulted in enucleation, if available
at the time then a combination of intra-arterial (n=4) and/or
intravitreal (n=3) chemotherapy and/or concomitant RD
surgery (n=5) would have been proposed in 9 of the 10 cases.
The remaining case, with evolution to phthisis bulbi despite
complete tumour control, would still be enucleated.
To date, while electroretinogram alterations have been
reported,38 the visual outcomes following globe salvage in uni-
lateral retinoblastoma have rarely been reported in the litera-
ture.4–10 39 In the majority of cases, successfully treated eyes
with preserved vision are amblyopic, but the results of the
present study indicate that this can be successfully overcome
and useful vision retained in a large proportion of eyes. In the
IAC group, signiﬁcantly better visual acuity was obtained; this
may be due to the quicker time to resolution that allowed
amblyopia therapy to begin sooner. While 7 of the 10 enu-
cleated eyes in the IVC group were free of macular involve-
ment at presentation, total RD was recorded in 6/7 of these
eyes during follow-up, indicative of lower visual potential.
Irrespective of whether these eyes could have been retained
and reasonable VA achieved, ﬁgure 3 indicates that this would
be insufﬁcient to reverse the trend of better visual acuity
afforded by IAC.
Theoretically, there is only a prophylactic beneﬁt against
metastases with IVC, but this cohort is inadequately powered to
indicate superiority in terms of the systemic control between the
two treatment types. On the other hand, a recent study pooling
the data from four centres (n=634) demonstrated that there was
no increase in mortality with IAC.40 On histopathological
examination, none of the enucleated eyes showed risk factors,
negating the need for adjuvant IVC. Despite these encouraging
results, there is a perceived increased metastatic risk associated
with IAC in advanced retinoblastoma.20 This fear originates
from the increased histopathological risk factors observed in
group D (17%) eyes following primary enucleation.41–43 In the
case of neoadjuvant chemotherapy, these risks would either pass
unnoticed if the eye is retained or be masked if secondary enu-
cleation was ﬁnally performed.44 If left untreated, the presence
of higher histopathological risk factors is expected to cause a
3% incidence of metastatic relapse, which can be reduced to
0.8% with adjuvant treatment in group D eyes.42 43 Preventive
systemic chemotherapy in the presence of histopathological risk
factors remains controversial as it exposes a large proportion of
patients unnecessarily to additional risks.40 In the future, high-
resolution MRI may play a role in determining which eyes
require adjuvant therapy by documenting the presence or
absence of radiological risk factors for minimally disseminated
disease, such as invasion of the choroid or the retrolaminar
portion of the optic nerve.45 Along the same lines, Torbidoni
et al46 recently described the infraclinical detection of micro-
metastasis using a cone-rod homeobox containing gene-
dependent assay, which could be combined with the molecular
detection of GD2 synthase mRNA in the cerebrospinal ﬂuid.47
Some intraoperative haemodynamic respiratory disturbances
were observed with IAC but all were transient. Episodes of neu-
tropenia observed with IVC were more severe than with IAC,
but none was life-threatening. With IAC, fewer general anaes-
thetics and shorter hospital stays were required, which indicates
large improvements in cost efﬁciency for health providers.
While IVC is available and widely decentralised, chemotherapy
delivery via the ophthalmic artery route requires skills that only
the most experienced interventional neuropediatric radiologists
will possess. Therefore, IAC is only achievable with a sufﬁcient
number of patients within a centralised secondary or tertiary
referral centre. However, we believe that the gains would more
than justify investment required to remodel the shared care net-
works in order to allow the widespread implementation of this
treatment modality.
The retrospective nature and the differences in adjunct treat-
ment modalities available at the time of treatment undermine this
comparison between groups. The introduction of IAC in 2008 as
salvage treatment for group D disease had not been an option for
the majority of the IVC group. We therefore excluded any subse-
quent cases combining IVC and IAC in order to compare the per-
formance as primary options. There was a signiﬁcant difference
between cohorts at baseline in terms of age; however, this is
likely an artefact of the minimum age limit for IAC treatment.
Furthermore, the advent of IViC has provided an efﬁcient FT for
vitreous seeding that was not available as second-line or salvage
treatment for most of the IVC group and is an unavoidable
source of bias. To examine this possible source of bias, we per-
formed subgroup analysis of eyes with vitreous seeding in the
IVC group and without IViC treatment in the IAC group, and we
observed that the primary outcomes were similar.
At present, IVC remains a valuable treatment option in bilat-
eral disease, children too young for IAC or in the rare cases of
failure of IAC due to anatomical factors. While more evidence is
required, the signiﬁcant advantages of IAC in terms of local
disease control, eye retention, visual function prognosis, time to
resolution, reduction in number of relapses and fewer retreat-
ments required indicate that, when available and provided add-
itional risk factors can be reliably identiﬁed, IAC is the
treatment of choice in group D unilateral disease.
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